Tag: Small Cell Lung Cancer
-
Jazz to Withdraw Zepzelca’s Second-Line SCLC Indication After Phase 3 Failure
Jazz plans to withdraw Zepzelca’s second-line small cell lung cancer indication after the Phase 3 LAGOON trial failed to confirm an overall survival benefit.